Intersect ENT, Inc. (NASDAQ:XENT) insider Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock in a transaction on Monday, October 16th. The stock was sold at an average price of $28.37, for a total transaction of $567,400.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Intersect ENT, Inc. (NASDAQ XENT) opened at 28.65 on Wednesday. Intersect ENT, Inc. has a 52 week low of $7.65 and a 52 week high of $33.25. The stock has a 50 day moving average of $30.18 and a 200 day moving average of $26.24. The firm’s market cap is $836.26 million.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.11. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The company had revenue of $24.00 million for the quarter, compared to analysts’ expectations of $22.62 million. During the same quarter last year, the business earned ($0.21) earnings per share. Intersect ENT’s revenue was up 24.4% on a year-over-year basis. Analysts anticipate that Intersect ENT, Inc. will post ($0.61) earnings per share for the current fiscal year.

WARNING: “Intersect ENT, Inc. (XENT) Insider Lisa D. Earnhardt Sells 20,000 Shares of Stock” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/intersect-ent-inc-xent-insider-lisa-d-earnhardt-sells-20000-shares-of-stock/1638196.html.

A number of research firms have weighed in on XENT. TheStreet upgraded shares of Intersect ENT from a “d” rating to a “c-” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded shares of Intersect ENT from a “sell” rating to a “hold” rating in a research note on Wednesday, July 26th. BidaskClub downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 price target on shares of Intersect ENT and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Finally, Canaccord Genuity reiterated a “buy” rating and set a $32.00 price target on shares of Intersect ENT in a research note on Wednesday, August 2nd. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Intersect ENT currently has a consensus rating of “Buy” and a consensus target price of $27.70.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc increased its position in shares of Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 255 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its stake in Intersect ENT by 109.1% in the first quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock valued at $196,000 after buying an additional 6,000 shares in the last quarter. Moors & Cabot Inc. acquired a new stake in Intersect ENT in the second quarter valued at about $205,000. Prudential Financial Inc. acquired a new stake in Intersect ENT in the second quarter valued at about $229,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Intersect ENT in the second quarter valued at about $229,000. Institutional investors own 83.12% of the company’s stock.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.